Markets, companies, property, jobs and trade

Home » Hims & Hers Launches Peptides+ Longevity Platform Across United States

Hims & Hers Launches Peptides+ Longevity Platform Across United States

By

–

Hims & Hers Launches Peptides+ Longevity Platform Across United States

SAN FRANCISCO, November 20, 2026 — Hims & Hers Health launched its Peptides+ longevity treatment platform across the United States on Wednesday, marking a major expansion of the telehealth company’s direct-to-consumer subscription model. The rollout brings compounded peptide and nutrient therapies to a national audience through the firm’s existing telehealth infrastructure.

The Offering

The Peptides+ platform includes compounded peptide and nutrient therapies such as sermorelin, NAD+, glutathione, vitamin B-12, and L-carnitine. The program is structured as a personalized service featuring at-home blood collection and ongoing clinical oversight for patients using the therapies.

By the Numbers

Hims & Hers carries a market capitalization of more than $3.5 billion. Synthetic peptides are a broad category of short-chain amino acids initially popular among bodybuilders that have since gained traction among a wider demographic seeking to optimize health, build muscle, increase energy, boost libido, or recover from injuries.

Regulatory Context

Many compounded peptides marketed to consumers are experimental and have not been approved by the Food and Drug Administration, nor are there randomized controlled trials demonstrating their safety and efficacy in humans. The Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has foregrounded the drug class; Kennedy is described as an avowed peptide enthusiast.

Industry Landscape

The launch coincides with a similar move by Noom, a private company valued at $3.7 billion, signaling a pivotal moment for peptide therapies entering the mainstream U.S. market. While smaller telehealth outfits have offered peptide prescriptions for some time, the entry of two dominant players shifts the competitive dynamics for digital health and wellness subscriptions.

What Investors Will Note

The Peptides+ rollout reinforces the narrative that Hims & Hers growth depends on layering higher-complexity, recurring specialties onto its telehealth and lab infrastructure. The catalyst around peptide-based therapies and at-home diagnostics sits alongside flagged risks, including legal scrutiny and a business mix that can pressure margins. Analysts tracking the stock point to a $28.85 fair value estimate as a reference for judging traction.

Sources

Photo: National Cancer Institute / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Markets & Wall Street

Transport & Aviation

Real Estate

Agriculture & Commodities